FR2234314B1 - - Google Patents

Info

Publication number
FR2234314B1
FR2234314B1 FR7421426A FR7421426A FR2234314B1 FR 2234314 B1 FR2234314 B1 FR 2234314B1 FR 7421426 A FR7421426 A FR 7421426A FR 7421426 A FR7421426 A FR 7421426A FR 2234314 B1 FR2234314 B1 FR 2234314B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7421426A
Other versions
FR2234314A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Ltd
Original Assignee
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP6865773A external-priority patent/JPS5320984B2/ja
Priority claimed from JP7436773A external-priority patent/JPS5320985B2/ja
Application filed by Teijin Ltd filed Critical Teijin Ltd
Publication of FR2234314A1 publication Critical patent/FR2234314A1/fr
Application granted granted Critical
Publication of FR2234314B1 publication Critical patent/FR2234314B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
FR7421426A 1973-06-20 1974-06-20 Expired FR2234314B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6865773A JPS5320984B2 (fr) 1973-06-20 1973-06-20
JP7436773A JPS5320985B2 (fr) 1973-07-03 1973-07-03

Publications (2)

Publication Number Publication Date
FR2234314A1 FR2234314A1 (fr) 1975-01-17
FR2234314B1 true FR2234314B1 (fr) 1978-03-31

Family

ID=26409859

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7421426A Expired FR2234314B1 (fr) 1973-06-20 1974-06-20

Country Status (7)

Country Link
US (1) US3936478A (fr)
AU (1) AU7014074A (fr)
BR (1) BR7405066D0 (fr)
CH (1) CH602788A5 (fr)
FR (1) FR2234314B1 (fr)
GB (1) GB1447456A (fr)
NL (1) NL167169C (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1595020A (en) * 1977-06-24 1981-08-05 Chugai Pharmaceutical Co Ltd 3a-hydroxy steroid derivatives of the cholestane series
US4145346A (en) * 1977-10-03 1979-03-20 Merck & Co., Inc. Preparation of 3β-hydroxy-27-norcholest-5-ene-25-one and intermediates thereof
EP0055999B1 (fr) * 1979-02-15 1984-10-03 Teijin Limited Vitamine D3
WO2003030857A1 (fr) * 2001-10-04 2003-04-17 Unilever Plc Renforcement du developpement de la barriere epidermique de la peau
AU2013259624B2 (en) 2012-05-08 2017-10-19 Lycera Corporation Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
MX2016010998A (es) 2014-02-27 2017-03-31 Lycera Corp Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
EP3140291A4 (fr) 2014-05-05 2018-01-10 Lycera Corporation Sulfonamide de tétrahydroquinoline et composés apparentés destinés à servir d'agonistes de rory et pour le traitement de maladies
WO2015171558A2 (fr) 2014-05-05 2015-11-12 Lycera Corporation Benzènesulfonamido et composés apparentés utilisés en tant qu'agonistes de rorγ et pour le traitement de maladie
EP3292119A4 (fr) 2015-05-05 2018-10-03 Lycera Corporation SULFONAMIDES DE DIHYDRO-2H-BENZO[B][1,4]OXAZINE ET COMPOSÉS APPARENTÉS DESTINÉS À ÊTRE UTILISÉS COMME AGONISTES DE RORy ET POUR LE TRAITEMENT DE MALADIES
US10611740B2 (en) 2015-06-11 2020-04-07 Lycera Corporation Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846455A (en) * 1972-05-22 1974-11-05 Eisai Co Ltd Process for the preparation of 25-hydroxy-cholesterol and esters thereof

Also Published As

Publication number Publication date
NL167169C (nl) 1981-11-16
FR2234314A1 (fr) 1975-01-17
US3936478A (en) 1976-02-03
CH602788A5 (fr) 1978-08-15
AU7014074A (en) 1975-12-18
BR7405066D0 (pt) 1975-01-21
DE2429644B2 (de) 1976-02-26
DE2429644A1 (de) 1975-01-09
GB1447456A (en) 1976-08-25
NL7408273A (fr) 1974-12-24

Similar Documents

Publication Publication Date Title
AU476761B2 (fr)
AU474593B2 (fr)
AU474511B2 (fr)
AU474838B2 (fr)
AU471343B2 (fr)
AU476714B2 (fr)
FR2234314B1 (fr)
AU476696B2 (fr)
AU472848B2 (fr)
AR199451A1 (fr)
AU477823B2 (fr)
AR197627A1 (fr)
AR195948A1 (fr)
AU476873B1 (fr)
AR196382A1 (fr)
AU471461B2 (fr)
AR195311A1 (fr)
AR193950A1 (fr)
AU477824B2 (fr)
AR196212Q (fr)
AR196123Q (fr)
AU7594774A (fr)
CH563122A5 (fr)
CH567709A5 (fr)
AU479453A (fr)

Legal Events

Date Code Title Description
ST Notification of lapse